Best Practice & Research Clinical Haematology最新文献_第7页

“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL) 儿童、青少年和青年非霍奇金淋巴瘤(NHL)的“科学现状”

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101482

Mitchell S. Cairo

引用次数: 0

Designing and conducting a clinical trial in blood and marrow transplantation 设计并进行血液和骨髓移植的临床试验

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101471

Michael J. Martens , Yan Gao , Aniko Szabo

{"title":"Designing and conducting a clinical trial in blood and marrow transplantation","authors":"Michael J. Martens , Yan Gao , Aniko Szabo","doi":"10.1016/j.beha.2023.101471","DOIUrl":"10.1016/j.beha.2023.101471","url":null,"abstract":"<div><p>Clinical trials<span> form the cornerstone of the science-based approach to improving patient outcomes. A trial needs to be designed and performed carefully to provide valid evidence to inform medical science and to protect the safety and well-being of its participants. The development of a clinical trial involving blood and marrow transplant (BMT) requires special considerations, including the rare disease populations involved and transplant-specific outcomes of interest that necessitate appropriate analysis techniques to evaluate.</span></p><p>This article reviews key considerations and best practices for the design and conduct of a clinical trial in BMT, including the selection of patient population, treatment groups, objectives and endpoints, targeted sample size, statistical analysis strategy, provisions for monitoring patient safety and trial progress, and dissemination of trial results. The practical application of these principles is demonstrated using BMT CTN 1301, a recently completed clinical trial evaluating regimens for chronic graft-versus-host disease prevention in transplant patients.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 2","pages":"Article 101471"},"PeriodicalIF":2.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9683350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What should be done and what should be avoided when comparing two treatments? 在比较两种治疗方法时，应该做什么，应该避免什么?

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101473

Florie Brion Bouvier , Raphaël Porcher

引用次数: 0

Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review 接受造血干细胞移植的白血病患者的财务毒性:一项系统综述

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101469

Orrin Pail , Thomas G. Knight

引用次数: 1

Handling missing covariate data in clinical studies in haematology 处理血液学临床研究中缺失的协变量数据

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101477

Edouard F. Bonneville , Johannes Schetelig , Hein Putter , Liesbeth C. de Wreede

{"title":"Handling missing covariate data in clinical studies in haematology","authors":"Edouard F. Bonneville , Johannes Schetelig , Hein Putter , Liesbeth C. de Wreede","doi":"10.1016/j.beha.2023.101477","DOIUrl":"10.1016/j.beha.2023.101477","url":null,"abstract":"<div><p>Missing data are frequently encountered across studies in clinical haematology. Failure to handle these missing values in an appropriate manner can complicate the interpretation of a study's findings, as estimates presented may be biased and/or imprecise. In the present work, we first provide an overview of current methods for handling missing covariate data, along with their advantages and disadvantages. Furthermore, a systematic review is presented, exploring both contemporary reporting of missing values in major haematological journals, and the methods used for handling them. A principal finding was that the method of handling missing data was explicitly specified in a minority of articles (in 76 out of 195 articles reporting missing values, 39%). Among these, complete case analysis and the missing indicator method were the most common approaches to dealing with missing values, with more complex methods such as multiple imputation being extremely rare (in 7 out of 195 articles). An example analysis (with associated code) is also provided using hematopoietic stem cell transplantation data, illustrating the different approaches to handling missing values. We conclude with various recommendations regarding the reporting and handling of missing values for future studies in clinical haematology.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 2","pages":"Article 101477"},"PeriodicalIF":2.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9688815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardio-oncology and transplantation for acute myeloid leukemia 急性髓性白血病的心脏肿瘤学和移植

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101465

Jai Singh

引用次数: 0

Take a spin: Apheresis in the care of adult leukaemia patients 看一看:血浆分离术在成人白血病患者护理中的应用

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101467

Jing Ai

引用次数: 0

Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia 急性髓系白血病同种异体移植患者可测量的残留疾病

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101468

Zoë C. Wong , Laura W. Dillon , Christopher S. Hourigan

{"title":"Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia","authors":"Zoë C. Wong , Laura W. Dillon , Christopher S. Hourigan","doi":"10.1016/j.beha.2023.101468","DOIUrl":"10.1016/j.beha.2023.101468","url":null,"abstract":"<div><p><span>The most common indication for allogeneic hematopoietic cell<span> transplant (alloHCT) is maintenance of remission after initial treatment for patients with </span></span>acute myeloid leukemia<span><span> (AML). Loss of remission, relapse, remains however the most frequent cause of alloHCT failure. There is strong evidence that detectable persistent disease burden (“measurable residual disease”, MRD) </span>in patients<span> with AML in remission prior to alloHCT is associated with increased risk of post-transplant relapse. MRD status as a summative assessment of response to pre-transplant therapy may allow superior patient-personalized risk stratification compared with models solely incorporating pre-treatment variables. An optimal methodology for AML MRD detection has not yet been established, but molecular methods such as DNA-sequencing may have additional prognostic utility compared to current approaches. There is growing evidence that intervention on AML MRD positivity may improve post-transplant outcomes. New initiatives will generate actionable data on the clinical utility of AML MRD testing for patients undergoing alloHCT.</span></span></p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 2","pages":"Article 101468"},"PeriodicalIF":2.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9767733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Allogeneic hematopoietic cell transplantation in acute myeloid leukemia 异基因造血细胞移植治疗急性髓性白血病

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101466

Gray Magee, Brittany Knick Ragon

引用次数: 0

Dermatologic complications in transplantation and cellular therapy for acute leukemia 急性白血病移植和细胞治疗中的皮肤并发症

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101464

Shahab Babakoohi , Stephanie L. Gu , Hamid Ehsan , Alina Markova

引用次数: 0